ARTL Artelo Biosciences, Inc.: רווח נקי למניה ב-12 החודשים האחרונים

Artelo Biosciences drug development is independent of economic cycles and seasonality. Artelo Biosciences aims for leadership in treating cancer-related pain and anorexia without psychoactive effects. The 12-month YoY EPS trend visualizes this dynamic, where the value 82.10 represents the most recent figure. However, regulatory complexities and a rapid cash burn before the completion of Phase II trials create significant risks.
Artelo - פילוחים אנליטיים ומדדי מפתח (ARTL)

This indicator captures the annual growth rate of net earnings per share over a rolling twelve-month period. The calculation model reflects profitability dynamics, reacting directly to quarterly reports and financial results. By analyzing the EPS YoY TTM relative change chart, an investor assesses the efficiency of business capitalization. For Artelo Biosciences (ARTL), this metric remains negative due to the absence of commercial products. Constant R&D expenditures preclude operating income, turning the metric into a marker for the capital burn rate.